Medical Advocates
Dapivirine (TMC 120) |
Last
Update:
May 26, 2017
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
Journal
Abstracts, Papers, and Commentaries
|
Balkus JE, Palanee-Phillips T, Reddy
K, et al
J Acquir Immune Defic Syndr. 2017 May
23.
In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine and
MIV-150: NNRTI Microbicides in Clinical Development for the Prevention
of HIV-1 Infection.
Giacobbi
NS, Sluis-Cremer N .Antimicrob
Agents Chemother. 2017 May 15.
Packing polymorphism of dapivirine and its impact on the performance of
a dapivirine-releasing silicone elastomer vaginal ring.
McCoy CF, Murphy DJ, Boyd P,
J
Pharm Sci. 2017 Apr 26
Abstract
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
Nel A, van Niekerk N, Kapiga S, et al
N Engl J Med.
2016 Dec;375(22):2133-2143.
Abstract
Pharmacokinetic Modeling of a Gel-Delivered Dapivirine Microbicide in Humans.
Halwes ME, Steinbach-Rankins JM, Frieboes HB.
Eur J Pharm Sci.
2016 Aug
21
Abstract
FULL-TEXT ARTICLE
Pharmacodynamic correlations using fresh and cryopreserved tissue following use
of vaginal rings containing dapivirine and/or maraviroc in a randomized,
placebo controlled trial. Dezzutti CS, Richardson-Harman N, Rohan LC,
et al Medicine
(Baltimore). 2016
Jul;95(28):e4174.
Paper
Dezzutti CS, Richardson-Harman N, Rohan LC,
et al
Medicine (Baltimore).(Baltimore).
2016 Jul;95(28):e4174.
Abstract
FULL TEXT ARTICLE
Safety,
Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical
Trial Conducted in Multiple Countries in Sub-Saharan Africa
Nel A, Bekker LG, Bukusi E, et al
PLoS One. 2016 Mar
10;11(3):e0147743
Paper
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
Baeten JM, Palanee-Phillips T, Brown ER,
et al
N Engl J Med. 2016 Feb 22
A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and
pharmacodynamics of a novel dapivirine vaginal film.
Bunge KE, Dezzutti CS, Rohan LC,et
al J Acquir Immune Defic Syndr. 2015 Nov 11
Abstract
Pharmacodynamic Activity of Dapivirine and Maraviroc Single
Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS, Yandura S, Wang L,
et al
Pharm Res.
2015 Jun
16.
Abstract
Protection against re in macaques by rectal specific-gel formulations of
maraviroc and tenofovir.ctal
SHIV transmission
Dobard CW, Taylor A, Sharma S,
et al
J Infect Dis. 2015 Jun 12|
Abstract
FULL TEXT ARTICLE
Characteristics of Women Enrolled into a Randomized Clinical Trial of
Dapivirine Vaginal Ring for HIV-1 Prevention.
Palanee-Phillips T, Schwartz K, Brown ER, et
al
PLoS One. 2015 Jun
10;10(6):e0128857. Paper
A safety and pharmacokinetic trial assessing delivery of dapivirine from
a vaginal ring in healthy women.
Nel A, Haazen
W, Nuttall J, Romano J, et al
AIDS.
2014 Jun 19;28(10):1479-87.
Abstract
FULL TEXT ARTICLE
Increased
Dapivirine tissue accumulation through vaginal film codelivery of
dapivirine and Tenofovir.
Akil A, Devlin B, Cost M,
Rohan LC. Mol Pharm.
2014 May
5;11(5):1533-41
Paper
Dual quantification of dapivirine and maraviroc in
cervicovaginal secretions from ophthalmic tear strips and
polyester-based swabs via liquid chromatographic-tandem mass
spectrometric (LC-MS/MS) analysis.
Parsons TL, Emory JF, Seserko LA, et al
J Pharm Biomed Anal. 2014 Sep;98:407-16.
Abstract
Pre-clinical development of a combination microbicide vaginal ring
containing dapivirine and darunavir.
Murphy DJ, Desjardins D, Dereuddre-Bosquet
N, et al
J Antimicrob Chemother.
2014 May 26.
Abstract
Development of dapivirine vaginal ring for HIV prevention.
Devlin B, Nuttall J, Wilder S, et al
Antiviral Res. 2013
Oct 24.
Abstract
|